# Endometriosis treatment Market > Endometriosis Treatment Market Research Report: Information by Treatment Type (Medication, Acupuncture Therapy, and Surgery), By End User (Hospitals & Clinics, Homecare Settings, and others), By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) -Global Forecast to 2035. - **Forecast Period:** 2025 - 2035 - **CAGR:** 13.5% - **2024:** $ 2,126.1 Million - **2035:** $ 8,427.32 Million - **Key Players:** Companies such as Pfizer Inc., Medtronic, AstraZeneca, F. Hoffmann-la Roche Ltd, Haleon Plc, AbbVie Inc., Bayer AG, Sanofi, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd. are some of the major participants in the global market. **Report ID:** MRFR/HC/19126-CR · **Pages:** 128 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 29, 2026 **URL:** https://www.marketresearchfuture.com/reports/endometriosis-treatment-market-20674 --- ## Market Summary The Global Endometriosis Treatment Market size was valued at USD 2,126.10 Million in 2024, and the market is projected to grow from USD 2,384.84 Million in 2025 to USD 8,427.32 Million by 2035, registering a CAGR of 13.5% during the forecast period 2025–2035. North America led the market in 2024 with over 45% share, generating around USD 1,156.93 Million in revenue.   Rising global prevalence of endometriosis, increasing awareness, and improved diagnostic capabilities are major growth drivers. Expanding women’s health initiatives and growing demand for non-invasive hormonal therapies are further accelerating treatment adoption and boosting market expansion worldwide.   According to the World Health Organization (WHO), endometriosis affects an estimated 10% of reproductive-age women globally, representing nearly 190 million women worldwide. The condition significantly impacts fertility and quality of life, with delayed diagnosis often exceeding 7–10 years, driving demand for early detection and advanced treatment solutions. ## Market Drivers ### Regulatory Support for New Treatments Regulatory support for new treatments is emerging as a vital driver for the Endometriosis Treatment Market. Regulatory agencies are increasingly recognizing the need for expedited approval processes for innovative therapies that address unmet medical needs in endometriosis management. This supportive regulatory environment encourages pharmaceutical companies to invest in the development of new drugs and treatment modalities.   For instance, the designation of orphan drug status for certain endometriosis treatments can provide incentives such as tax credits and market exclusivity, fostering innovation. As regulatory frameworks evolve to accommodate advancements in treatment, the market is likely to benefit from a more robust pipeline of effective therapies. ### Rising Awareness and Advocacy Efforts Rising awareness and advocacy efforts surrounding endometriosis are significantly influencing the Endometriosis Treatment Market. Non-profit organizations and patient advocacy groups are actively working to educate the public and healthcare professionals about the condition, its symptoms, and the importance of timely diagnosis. This heightened awareness is leading to increased patient engagement and a greater willingness to seek treatment.   Furthermore, campaigns aimed at reducing the stigma associated with menstrual disorders are encouraging women to discuss their symptoms openly, thereby facilitating earlier intervention. As awareness continues to grow, the demand for effective treatment options is expected to rise, driving the expansion of the market. ### Increasing prevalence of endometriosis The Endometriosis Treatment Market is expanding due in significant part to the rising incidence of endometriosis. The development of endometrial-like tissue outside the uterus is the hallmark of endometriosis, a chronic gynecological condition that causes symptoms like tiredness, infertility, dysmenorrhea, and persistent pelvic discomfort. The demand for therapeutic medications, surgical procedures, and efficient. ### Increasing adoption of hormonal therapies for symptom management Hormonal therapy represents the cornerstone of endometriosis treatment, as these drugs suppress estrogen production and slow the growth of endometrial-like tissue outside the uterus. Physicians widely prescribe oral contraceptives, progestins, and gonadotropin-releasing hormone (gnrh) modulators to control pelvic pain, dysmenorrhea, and disease progression. As awareness of long-term hormonal management increases, more patients are opting for pharmacological treatment rather than relying solely on surgery, which is driving growth in the endometriosis treatment market.  ## Future Outlook The Endometriosis Treatment Market size is projected to reach USD 8,427.32 Million by 2035, growing at a CAGR of 13.5%, driven by increasing demand for high-performance computing and enhanced security features. **New opportunities:** - Increasing investment in women’s health. Expansion of Pipeline Drugs and Clinical Research. By 2035, the Endometriosis Treatment Market is expected to achieve substantial growth, reflecting advancements in treatment and patient care. ## Segment Insights ### By Treatment Type: Medication (largest market) vs Surgery (fastest growing) Based on Treatment Type, the Endometriosis Treatment Market has been segmented into Medication, Acupuncture Therapy, and Surgery. Medication is further segmented into NSAIDs, Oral Contraceptives, Gonadotropin Releasing Hormone Agonists and Antagonists, and others. The Medication segment held the largest market share of 72% in 2025; the medication segment is the fastest-growing segment during the forecast period. ### By End User: Hospitals & Clinics (largest market) vs Homecare (fastest-growing) Based on end user, the Endometriosis Treatment Market has been segmented into Hospitals & Clinics, Homecare Settings, and others. The Hospitals & Clinics segment held the largest market share, 78% in 2025, and the Homecare Settings segment is the fastest-growing segment during the forecast period. ## Regional Market Share Analysis ### North America**:**Expanding global endometriosis treatment North America accounts for the largest share of the Endometriosis Treatment Market, typically around 40–50% of total revenue, driven by high awareness, advanced healthcare infrastructure, and strong reimbursement coverage. The U.S. dominates the region, supported by robust pharmaceutical R&D, early adoption of oral GnRH antagonists (e.g., relugolix‑based combinations), and supportive policy initiatives such as the Endometriosis CARE Act aimed at improving research funding and access. Canada and Mexico are growing steadily, with increasing diagnosis rates and uptake of hormonal therapies, [analgesics](https://www.marketresearchfuture.com/reports/analgesics-market-19195), and laparoscopic surgery, making North America the primary revenue hub and innovation center for endometriosis treatments. - The Centers for Disease Control and Prevention (CDC) reports that infertility affects about 6% of married women aged 15–44 in the United States, with endometriosis being a leading contributing condition. Additionally, laparoscopic diagnostic procedures have significantly improved early detection rates, supporting faster treatment initiation and higher therapeutic success rates across North America. ### Europe: Strong Production universal‑healthcare systems Europe represents a mature but dynamic market, characterized by universal‑healthcare systems, standardized diagnostic protocols, and strong women’s‑health advocacy. Countries such as Germany, the U.K., France, Italy, and Spain lead in the uptake of hormonal therapies, including oral contraceptives, progestins, and GnRH agonists/antagonists, often combined with multidisciplinary care pathways that integrate pain management and fertility counseling. Market growth is tempered by stringent EMA‑level drug‑approval processes and price controls in some markets, yet Eastern and Southern European countries are seeing gradual expansion as diagnostic access and specialist‑led care improve. Europe is also a key center for advanced surgical techniques, particularly minimally invasive laparoscopy, reinforcing its role in the global endometriosis care ecosystem. - The European Centre for Disease Prevention and Control (ECDC) highlights that chronic gynecological disorders contribute significantly to women’s healthcare burden in Europe, where structured national screening and hospital-based diagnostic systems have improved early detection rates by 20–30% in several member states. Enhanced access to laparoscopic surgery and hormonal therapies continues to support improved long-term patient outcomes. ### Asia Pacific: Rising healthcare spending Asia Pacific (APAC) is the fastest‑growing region, with double‑digit CAGRs projected over the next decade due to rising healthcare spending, urbanization, and expanding women’s‑health programs. China leads the growth trajectory, supported by government‑backed initiatives to improve early diagnosis, wider availability of imaging‑based diagnostics, and partnerships between global pharma and local manufacturers for hormonal therapies and novel agents.  India, Japan, South Korea, and Australia also contribute, with Japan and Australia serving as early‑adopters of advanced hormonal and non‑hormonal therapies, while India and Southeast Asia offer large‑volume, price‑sensitive markets for generics and more affordable branded products. As awareness and diagnostic infrastructure improve, APAC is expected to overtake other regions in incremental growth over the long term. ### South America: Protection of stronger women’s‑health advocacy South America (Latin America) is a smaller but increasingly important segment, with Brazil and Argentina leading the regional market. Brazil’s large population and growing middle class support rising demand for hormonal therapies, analgesics, and minimally invasive surgery, while public‑health programs such as the Sistema Único de Saúde (SUS) are gradually expanding access to endometriosis diagnosis and care. Argentina and other Andean and Southern Cone countries are seeing similar trends, albeit at a slower pace, as specialists adopt international guidelines and generic hormonal products gain share. Overall, South America is expected to grow steadily, driven by improving diagnosis rates, urbanization, and stronger women’s‑health advocacy, making it a notable secondary growth pocket within the global endometriosis treatment landscape. ### Middle East & Africa: Emerging treatment penetration Middle East and Africa (MEA) remains a relatively underpenetrated but emerging market, with the Gulf Cooperation Council (GCC) countries and South Africa accounting for the majority of current activity. Private‑sector‑driven healthcare in the GCC enables higher uptake of innovative hormonal therapies and laparoscopic surgery, especially among affluent urban populations, while public‑health systems in countries like South Africa face constraints around cost and workforce capacity. Awareness campaigns and NGO‑led advocacy are beginning to shorten diagnostic delays, particularly in South Africa and Egypt, but overall treatment penetration remains lower than in North America, Europe, and parts of APAC. MEA is therefore positioned as a mid‑term growth region, where access improvements and selective reimbursement reforms could unlock substantial latent demand. ## Competitive Benchmarking Many global, regional, and local vendors characterize the Endometriosis Treatment Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in Treatment, frequent changes in government policies, and environmental regulations are key factors that confront market growth.   The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.   The major players in the market Include Pfizer Inc., Medtronic, AstraZeneca, F. Hoffmann-la Roche Ltd, Haleon Plc, AbbVie Inc., Bayer AG, Sanofi, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd strategic market developments and decisions to improve operational effectiveness. ## Recent News & Developments Pfizer Inc., Medtronic, AstraZeneca, F. Hoffmann-la Roche Ltd, Haleon Plc, AbbVie Inc., Bayer AG, Sanofi, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd. August 2025: The U.S. FDA approved MYFEMBREE as a once-daily oral therapy for the management of moderate to severe pain associated with endometriosis in premenopausal women. The approval was supported by Phase 3 SPIRIT 1 and SPIRIT 2 trials involving more than 1,200 patients, demonstrating significant reduction in menstrual and non-menstrual pelvic pain with minimal bone mineral density loss. The product is jointly commercialized in the U.S. by Myovant Sciences and Pfizer. April 2025: Medtronic is leveraging its robust product pipeline to accelerate revenue growth, driven by favourable market conditions, recent product launches, and a strong innovation pipeline, which is expected to fuel growth in both the near and long term. The company focuses on delivering innovative, disruptive technologies that address large healthcare challenges, enabling them to better meet patient needs.. March 2025: AstraZeneca’s strategic vision is centered on achieving industry-leading growth through a diversified portfolio across key therapeutic areas and a broad geographic presence. The company is dedicated to transforming healthcare by collaborating with governments, healthcare systems, and providers to reduce the global burden of disease and enhance the resilience of healthcare infrastructure for future generations. AstraZeneca aims to improve patient outcomes by focusing on proactive screening and early diagnosis, encouraging guideline adoption at the practice level, optimizing specialist pathways for personalized care, and strengthening health systems to deliver integrated, patient-centered care. ## Report Scope | Market End User 2024 |  2,126.10 (USD Million) | | --- | --- | | Market End User 2025 | 2,384.84 (USD Million) | | Market End User 2035 |  8,427.32 (USD Million) | | Compound Annual Growth Rate (CAGR) | 13.5% (2025 - 2035) | | Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | Base Year | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2023 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer Inc., Medtronic, AstraZeneca, F. Hoffmann-la Roche Ltd, Haleon Plc, AbbVie Inc., Bayer AG, Sanofi, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd. | | Segments Covered | By Treatment Type By End User By Deployment Lauch Type By Application | | Key Market Opportunities | Increasing investment in women’s health Expansion of Pipeline Drugs and Clinical Research | | Key Market Dynamics | Growing Use of Combination and Long-Term Drug Therapies Increasing Treatment Uptake for Endometriosis-Associated Pain and Infertility | | Region Covered | North America, Europe, Asia Pacific, South America, Middle East & Africa. | ## Frequently Asked Questions **Q: How much is the Endometriosis Treatment Market?** A: USD 8,427.32 Million (2035) is the Endometriosis Treatment Market **Q: What is the growth rate of the Endometriosis Treatment Market?** A: 13.5% is the growth rate of the Endometriosis Treatment Market **Q: Which region held the largest market share in the Endometriosis Treatment Market?** A: North America held the largest market share in the Endometriosis Treatment Market. **Q: Who are the key players in the Endometriosis Treatment Market?** A: Pfizer Inc., Medtronic, AstraZeneca, F. Hoffmann-la Roche Ltd, Haleon Plc, AbbVie Inc., Bayer AG, Sanofi, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd. **Q: Which Application had the largest market share in the Endometriosis Treatment Market?** A: Hospitals & Clinics had the largest market share in the Endometriosis Treatment Market. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/endometriosis-treatment-market-20674*